Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Notes Payables: 2014-2020

Historic Notes Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Sep 2020 value amounting to $4.7 million.

  • Viridian Therapeutics, Inc.\DE's Notes Payables fell 49.01% to $4.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $4.7 million, marking a year-over-year decrease of 49.01%. This contributed to the annual value of $4.0 million for FY2019, which is 61.39% down from last year.
  • As of Q3 2020, Viridian Therapeutics, Inc.\DE's Notes Payables stood at $4.7 million, which was up 37.75% from $3.4 million recorded in Q2 2020.
  • Viridian Therapeutics, Inc.\DE's 5-year Notes Payables high stood at $10.3 million for Q4 2018, and its period low was $1.1 million during Q1 2016.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Notes Payables value was $9.2 million (recorded in 2019), while the average stood at $7.5 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Notes Payables skyrocketed by 333.39% in 2016, and later plummeted by 67.07% in 2019.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Notes Payables (Quarterly) stood at $4.8 million in 2016, then spiked by 107.18% to $9.9 million in 2017, then climbed by 3.79% to $10.3 million in 2018, then tumbled by 61.39% to $4.0 million in 2019, then slumped by 49.01% to $4.7 million in 2020.
  • Its last three reported values are $4.7 million in Q3 2020, $3.4 million for Q2 2020, and $7.4 million during Q1 2020.